In vivo therapeutic synergism of anti-epidermal growth factor receptor and anti-HER2 monoclonal antibodies against pancreatic carcinomas.

@article{Larbouret2007InVT,
  title={In vivo therapeutic synergism of anti-epidermal growth factor receptor and anti-HER2 monoclonal antibodies against pancreatic carcinomas.},
  author={Christel Larbouret and Bruno G{\'e}rard Michel Robert and Isabelle Navarro-Teulon and Simon Th{\'e}z{\'e}nas and Maha-Zohra Ladjemi and S{\'e}bastien Morisseau and Emmanuelle Campigna and Fr{\'e}d{\'e}ric Bibeau and J. -P. Mach and Andr{\'e} Pelegrin and David Azria},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2007},
  volume={13 11},
  pages={3356-62}
}
PURPOSE Pancreatic carcinoma is highly resistant to therapy. Epidermal growth factor receptor (EGFR) and HER2 have been reported to be both dysregulated in this cancer. To evaluate the in vivo effect of binding both EGFR and HER2 with two therapeutic humanized monoclonal antibodies (mAb), we treated human pancreatic carcinoma xenografts, expressing high EGFR and low HER2 levels. EXPERIMENTAL DESIGN Nude mice, bearing xenografts of BxPC-3 or MiaPaCa-2 human pancreatic carcinoma cell lines… CONTINUE READING
41 Citations
33 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 41 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 33 references

Similar Papers

Loading similar papers…